UNAIDS and WHO estimate that of the 40 million people living with HIV/AIDS in the world, approximately 2.8 million are 50 years and older. In the US, an estimated 1 million people are infected with HIV, although one- third of this population is unaware of their diagnosis. While HIV infection is commonly thought to affect younger adults, there are an increasing number of patients over 50 years of age living with the condition. With the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, survival following HIV diagnosis has risen dramatically and HIV infection has evolved from an acute disease process to being managed as a chronic medical condition. Over the past two decades, significant progress has been made in understanding HIV pathogenesis and disease progression, which has allowed the identification of a multitude of drug and vaccine targets. Although currently available drug therapies have greatly increased the time from HIV infection to development of AIDS, drug resistance is an inevitable consequence that limits the duration of successful treatment. In this proposal we are targeting a step in viral life cycle that is essential for viral survival and to date there are no therapeutics against this particular pathway. HIV-1 uses Tat as its viral activator and viruses mutated in Tat are not viable. We are planning to continue our work on Tat peptide derivatives (mimetics) inhibitors that could potentially inhibit virus replication both in cell culture and our humanized animal models. From our original submission, we have successfully been able to trim the original Tat 15 aa peptide inhibitor to 5 aa and have found the new peptide to be able to bind to cdk2, and cdk9 tightly and inhibit their kinase activity both in vitro and in vivo. The new peptide and its mimetic (which was not planned in the original proposal) show promising results in inhibiting HIV-1 replication in cell lines and PBMCs through various mechanisms. In the current proposal we are completely focusing on the mimetics and not the peptides anymore. We will extend our initial observations in PBMCs to various pharmacological parameters including cytotoxicity, inhibitory concentrations, and its ability to inhibit replication of numerous viral strains including patient isolates and drug and resistant strains. The inhibition studies will be performed with the two 2 generation mimetics, F07#13 and F07#19, which will allow us to select the best possible inhibitors for a given HIV clade or stain. We will also ask about the functional consequence of SWI/SNF phosphorylation by cdk2/E in relation to HIV-1 chromatin remodeling of nucleosomes. Finally, we will examine the effect of cdk9 phosphorylation by cdk2/E in presence of chromatinized HIV-1 LTR DNA. We will use in vitro biotin DNA transcription assays that uses Tat for activated transcription with and without added cdk2/E and ask in cdk9 can get phosphorylated at any of the 175, 186, 262, 347 and 363 sites. Collectively, our new mimetic inhibitors and better definition of its targets will aid in bringing a new Tat inhibitor to the clinic.

Public Health Relevance

In view of the urgency of the AIDS epidemic, it is essential to learn about the function of specific viral inhibitors for proteins such as Tat that play a key role in pathogenesis. The understanding of how HIV-1 Tat manipulates the transcription machinery will aid in designing better Tat inhibitors of mimetic nature.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI043894-13
Application #
8494511
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Miller, Roger H
Project Start
1999-07-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$350,640
Indirect Cost
$81,531
Name
George Mason University
Department
Public Health & Prev Medicine
Type
Schools of Arts and Sciences
DUNS #
077817450
City
Fairfax
State
VA
Country
United States
Zip Code
22030
Kumari, Namita; Iordanskiy, Sergey; Kovalskyy, Dmytro et al. (2014) Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase I?B-? expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription. Antimicrob Agents Chemother 58:6558-71
Sampey, Gavin C; Meyering, Shabana S; Asad Zadeh, Mohammad et al. (2014) Exosomes and their role in CNS viral infections. J Neurovirol 20:199-208
Chen, Hao; Zhao, Yunjie; Li, Haotian et al. (2014) Break CDK2/Cyclin E1 interface allosterically with small peptides. PLoS One 9:e109154
Jaworski, Elizabeth; Narayanan, Aarthi; Van Duyne, Rachel et al. (2014) Human T-lymphotropic virus type 1-infected cells secrete exosomes that contain Tax protein. J Biol Chem 289:22284-305
Narayanan, Aarthi; Iordanskiy, Sergey; Das, Ravi et al. (2013) Exosomes derived from HIV-1-infected cells contain trans-activation response element RNA. J Biol Chem 288:20014-33
Van Duyne, Rachel; Guendel, Irene; Jaworski, Elizabeth et al. (2013) Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. J Mol Biol 425:812-29
Narasipura, Srinivas D; Henderson, Lisa J; Fu, Sidney W et al. (2012) Role of *-catenin and TCF/LEF family members in transcriptional activity of HIV in astrocytes. J Virol 86:1911-21
Tyagi, Mudit; Kashanchi, Fatah (2012) New and novel intrinsic host repressive factors against HIV-1: PAF1 complex, HERC5 and others. Retrovirology 9:19
Van Duyne, Rachel; Guendel, Irene; Narayanan, Aarthi et al. (2011) Varying modulation of HIV-1 LTR activity by Baf complexes. J Mol Biol 411:581-96
Easley, Rebecca; Carpio, Lawrence; Dannenberg, Luke et al. (2010) Transcription through the HIV-1 nucleosomes: effects of the PBAF complex in Tat activated transcription. Virology 405:322-33

Showing the most recent 10 out of 52 publications